Company news

RenovoRx, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review

August 14, 2025

RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire

August 6, 2025

RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors

July 28, 2025

RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4: 30 p.m. ET

July 14, 2025

RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights

May 15, 2025

RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st

May 14, 2025

U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform

May 6, 2025

RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4: 30 p.m. ET

May 1, 2025

Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx’s Ongoing Phase III TIGeR-PaC Clinical Trial

April 29, 2025

RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community

April 16, 2025

RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th

April 4, 2025

RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

April 1, 2025

RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting

March 28, 2025

RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting

March 26, 2025

RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12: 00 p.m. ET

March 20, 2025

RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025

March 19, 2025

RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders

February 26, 2025

RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery

February 12, 2025

RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock

February 10, 2025

RenovoRx Announces Proposed Public Offering

February 5, 2025

RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock

February 5, 2025

RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025

January 26, 2025

RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025

January 7, 2025

RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform

December 29, 2024

RenovoRx Initiates Patient Enrollment at SCRI Oncology Partners for Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer

December 10, 2024

RenovoRx CEO to Host Investor Fireside Chat on Tuesday, December 17th at 4: 30 p.m. ET

December 9, 2024

RenovoRx Receives First Purchase Orders for its FDA-Cleared RenovoCath® Delivery System

December 4, 2024

Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx’s Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

November 19, 2024

RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights

November 13, 2024

RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians

September 24, 2024

RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer

September 18, 2024

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright’s 26th Annual Global Investment Conference on September 9, 2024 in New York

August 26, 2024

RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

August 13, 2024

RenovoRx Announces Publication of Positive Early-Stage Clinical Data in International Peer-Reviewed Journal, The Oncologist®

July 30, 2024

RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist®

July 7, 2024

University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx’s Pivotal Phase III TIGeR-PaC Clinical Trial

June 25, 2024

RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

June 9, 2024

RenovoRx CEO Issues Update Letter to Shareholders

May 29, 2024

Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx’s TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery

May 20, 2024

RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024

May 13, 2024

RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024

May 1, 2024

RenovoRx Regains Compliance with Nasdaq Stockholders’ Equity Requirement

April 17, 2024

RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting

April 15, 2024

RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026

April 14, 2024

RenovoRx Announces $11.1 Million at Market Private Placement

April 7, 2024

RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024

April 4, 2024

RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024

March 11, 2024

RenovoRx Highlights Key Leadership Promotions

March 7, 2024

RenovoRx CEO Issues Letter to Shareholders

February 5, 2024

RenovoRx Closes $6.1 Million Private Placement

January 28, 2024

← Newer news releases · Older news releases →

Calls

The 5 newest of 6 calls. Every call is listed under its year.

Decks